Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase Ib and Pharmacokinetic Study

• Published in: Cancer prevention research (Philadelphia, Pa.) Vol. 7; no. 3; pp. 283 - 291
• Main Authors: Saba, Nabil F., Hurwitz, Selwyn J., Kono, Scott A., Yang, Chung S., Zhao, Yang, Chen, Zhengjia, Sica, Gabe, Müller, Susan, Moreno-Williams, Rachel, Lewis, Melinda, Grist, William, Chen, Amy Y., Moore, Charles E., Owonikoko, Taofeek K., Ramalingam, Suresh, Beitler, Jonathan J., Nannapaneni, Sreenivas, Shin, Hyung Ju C., Grandis, Jennifer R., Khuri, Fadlo R., Chen, Zhuo Georgia, Shin, Dong M.
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.03.2014
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Squamous Cell - metabolism; Carcinoma, Squamous Cell - prevention & control; Celecoxib; Chemoprevention - methods; Disease Progression; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms - metabolism; Head and Neck Neoplasms - prevention & control; Humans; Male; Medical sciences; Middle Aged; Miscellaneous; Otorhinolaryngology (head neck, general aspects and miscellaneous); Otorhinolaryngology. Stomatology; Prevention and actions; Public health. Hygiene; Public health. Hygiene-occupational medicine; Pyrazoles - administration & dosage; Pyrazoles - pharmacokinetics; Quinazolines - administration & dosage; Quinazolines - pharmacokinetics; Sulfonamides - administration & dosage; Sulfonamides - pharmacokinetics; Tumors; Antineoplastic agent; Prostaglandin-endoperoxide synthase; Chemoprophylaxis; Enzyme; Tyrosine kinase inhibitor; Quinazoline derivatives; Transferases; Enzyme inhibitor; Cyclooxygenase 2 inhibitor; Malignant tumor; Celecoxib; Non steroidal antiinflammatory agent; Prevention; Chemotherapy; Treatment; Erlotinib; ENT disease; Head and neck cancer; Oxidoreductases; Pharmacokinetics; Protein-tyrosine kinase; Cancer

Epidermal growth factor receptor (EGFR) and COX-2 inhibitors synergistically inhibit head and neck squamous cell carcinoma tumorigenesis in preclinical studies. We conducted a phase I and pharmacokinetic study with the erlotinib and celecoxib combination in patients with advanced premalignant lesion...